In our current study, we synthesized a small peptide TAT-NLS-BLBD-6 (ATDEMIPF), which is a Wnt/β-catenin signaling inhibitor and prevents the binding of β-catenin to LEF-1 at the nuclear region of human breast cancer cells. Here, LEF1 is linked to breast cancer.